Performance measures in Friedreich ataxia: Potential utility as clinical outcome tools

被引:36
|
作者
Lynch, DR
Farmer, JM
Wilson, RL
Balcer, LJ
机构
[1] Childrens Hosp Philadelphia, Div Neurol, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA
[3] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA
[4] Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
关键词
composite measure; mitochondrial disease; antioxidant; cardiomyopathy; diabetes;
D O I
10.1002/mds.20449
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Although several neuroprotective agents have been proposed as potential therapies in Friedreich ataxia (FA), clinical trials of their efficacy are limited by a lack of sensitive outcome measures. We assessed whether performance measures (nine-hole peg test, the timed 25-foot walk, and low-contrast letter acuity) provide valid measures of disease status in FA. Scores for each measure correlated significantly with neurologic disability and disease duration. Rank correlations between scores for performance measures were moderate in magnitude, Suggesting that the each test captures separate yet related dimensions of neurological function in FA. Linear regression models demonstrated that scores from the nine-hole peg test and the timed 25-foot walk (after reciprocal transformation) were predicted by age and triplet repeat length in patients with FA. In addition, comparison of the temporal courses of change for each performance measure demonstrated that scores from the timed 25-foot walk change early in the Course of FA, nine-hole peg test scores change slowly over the full course of the disorder, and low-contrast letter acuity scores change in the later stages of the disease. Thus, a composite scale derived from these performance measures may provide the best overall measure for assessing disease progression throughout the illness. (c) 2005 Movement Disorder Society.
引用
收藏
页码:777 / 782
页数:6
相关论文
共 50 条
  • [21] Health related quality of life measures in Friedreich Ataxia
    Epstein, Elizabeth
    Farmer, Jennifer M.
    Tsou, Amy
    Perlman, Susan
    Subramony, S. H.
    Gomez, Christopher M.
    Ashizawa, Tetsuo
    Wilmot, George R.
    Mathews, Katherine
    Wilson, Robert B.
    Balcer, Laura J.
    Lynch, David R.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2008, 272 (1-2) : 123 - 128
  • [22] Spectral measures of the effects of Friedreich's ataxia on speech
    Rosen, Kristin M.
    Folker, Joanne E.
    Murdoch, Bruce E.
    Vogel, Adam P.
    Cahill, Louise M.
    Delatycki, Martin B.
    Corben, Louise A.
    INTERNATIONAL JOURNAL OF SPEECH-LANGUAGE PATHOLOGY, 2011, 13 (04) : 329 - 334
  • [23] Omaveloxolone: potential new agent for Friedreich ataxia
    Lynch, David R.
    Johnson, Joseph
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2021, 11 (02) : 91 - 98
  • [24] A rapid, noninvasive immunoassay for frataxin: Utility in assessment of Friedreich ataxia
    Deutsch, Eric C.
    Santani, Avni B.
    Perlman, Susan L.
    Farmer, Jennifer M.
    Stolle, Catherine A.
    Marusich, Michael F.
    Lynch, David R.
    MOLECULAR GENETICS AND METABOLISM, 2010, 101 (2-3) : 238 - 245
  • [25] Cardiomyopathy in Friedreich Ataxia: Clinical Findings and Research
    Payne, R. Mark
    Wagner, Gregory R.
    JOURNAL OF CHILD NEUROLOGY, 2012, 27 (09) : 1179 - 1186
  • [26] Friedreich's ataxia: A clinical and genetic analysis
    Reddy, P. Leema
    Grewal, Raji P.
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2007, 109 (02) : 200 - 202
  • [27] Consensus clinical management guidelines for Friedreich ataxia
    Louise A Corben
    David Lynch
    Massimo Pandolfo
    Jörg B Schulz
    Martin B Delatycki
    Orphanet Journal of Rare Diseases, 9
  • [28] Friedreich's ataxia: Clinical aspects and pathogenesis
    Pandolfo, M
    SEMINARS IN NEUROLOGY, 1999, 19 (03) : 311 - 321
  • [29] Friedreich Ataxia: Dysarthria Profile and Clinical Data
    Brendel, Bettina
    Ackermann, Hermann
    Berg, Daniela
    Lindig, Tobias
    Schoelderle, Theresa
    Schoels, Ludger
    Synofzik, Matthis
    Ziegler, Wolfram
    CEREBELLUM, 2013, 12 (04): : 475 - 484
  • [30] Clinical Experience With Deferiprone Treatment for Friedreich Ataxia
    Elincx-Benizri, Sandra
    Glik, Amir
    Merkel, Drorit
    Arad, Michael
    Freimark, Dov
    Kozlova, Evgenia
    Cabantchik, Ioav
    Hassin-Baer, Sharon
    JOURNAL OF CHILD NEUROLOGY, 2016, 31 (08) : 1036 - 1040